Uptake and effect of radioiodine exposure on SKBR-3 cell lines

Miftah Irramah, Yulia Kurniawati, VY Susilo, S Setiyowati, Aisyah Elliyanti


Radioiodine has been known as an adjuvant therapy for thyroid cancer. Beside for thyroid cell, radioiodine is reported to be taken up by breast cell. It may be proposed as an alternative for breast cancer therapy. Objective: The study aim was to analyze an uptake of radioiodine and cell proliferation rate of breast cancer cell after the exposure of radioiodine. Methods: This study used SKBR-3 cell line as representative of Human Epidermal Growth Factor Receptor (HER2+) subtype. The cells were planted in DMEM medium added 10% fetal bovine serum (FBS), panstrep 1% and amphotericin B. The cells were grown until 80% confluent and then stripped. Subsequently the cells were sub-cultured on plates 12 and 6 wells respectively for measured uptake of radioiodine and cell proliferation rate after the exposure. Radioiodine uptake was calculated by sum efflux of 125 Iodine (125I) and the amount of uptake after the addition of 95% ethanol. Cell proliferation rate was measured by calculated by using clonogenic assay after iodine-131 (131I) exposure. Results: The average of iodine uptake was 194±50 cpm/106 cell. The average cell proliferation after radioiodine exposure was 54%±5%; Conclusions: Radioiodine is taken by SKBR-3 cells and it reduced cell proliferation rate. This finding shows an opportunity for radioiodine as an alternative therapy for breast cancer. Another studies are needed to understand of cell death the mechanism.


radioiodine; proliferation; uptake

Full Text:



American Cancer Society. The Costs of Cancer. [Internet]. 2017. Available in: [Link].

Aysola K, Desai A, Welch C, Xu J, Qin Y, Reddy V, et al. Triple Negative Breast Cancer – An Overview. Hereditary Genet. 2013; 2013(Suppl 2):001. doi: 10.4172/2161-1041.S2-001. [PMC free article].

O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, et al. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res. 2010; 16(24):6100-10. doi: 10.1158/1078-0432.CCR-10-1533. [PubMed] [PMC free article].

Reddy S, Charles M, Kumar M, Reddy B, Anjaneyulu C, Raju G, et al. Differentiated Thyroid Cancer-Treatment: State of the Art. Int J Mol Sci. 2017; 18(6):E1292. doi: 10.3390/ijms18061292. [PubMed] [PMC free article].

Micali S, Bulotta S, Puppin C, Territo A, Navarra M, Bianchi G, et al. Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer. BMC Cancer. 2014; 14:303. doi: 10.1186/1471-2407-14-303. [PubMed] [PMC free article].

Hingorani M, Spitzweg C, Vassaux G, Newbold K, Melcher A, Pandha H, et al. The biology of the sodium iodide symporter and its potential for targeted gene delivery. Curr Cancer Drug Targets. 2010; 10(2):242-67. doi: 10.2174/156800910791054194. [PubMed] [PMC free article].

Elliyanti A, Putra AE, Sribudiani Y, Noormartany N, Masjhur JS, Achmad TH, et al. Epidermal Growth Factor and Adenosine Triphosphate Induce Natrium Iodide Symporter Expression in Breast Cancer Cell Lines. Open Access Maced J Med Sci. 2019; 7(13):2088-2092. doi: 10.3889/oamjms.2019.620. [PubMed] [PMC free article].

Knostman KA, Cho JY, Ryu KY, Lin X, McCubrey JA, Hla T, et al. Signaling through 3′, 5′-cyclic adenosine monophosphate and phosphoinositide-3 kinase induces sodium/iodide symporter expression in breast cancer. J Clin Endocrinol Metab. 2004; 89(10):5196-203. doi: 10.1210/jc.2004-0907. [PubMed].

Kogai T, Taki K, Brent G. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer. 2006; 13(3):797-826. doi: 10.1677/erc.1.01143. [PubMed].

Hieu TT, Russell AW, Cuneo R, Clark J, Kron T, Hall P, et al. Cancer risk after medical exposure to radioactive iodine in benign thyroid diseases: a meta-analysis. Endocr Relat Cancer. 2012; 19(5):645-55. doi: 10.1530/ERC-12-0176. [PubMed].

Nielsen SM, White MG, Hong S, Aschebrook-Kilfoy B, Kaplan EL, Angelos P, et al. The Breast-Thyroid Cancer Link: A Systematic Review and Meta-analysis. Cancer Epidemiol Biomarkers Prev. 2016; 25(2):231-8. doi: 10.1158/1055-9965. [PubMed] [PMC free article].

Dong L, Lu J, Zhao B, Wang W, Zhao Y. Review of the possible association between thyroid and breast carcinoma. World J Surg Oncol. 2018; 16(1):130. doi: 10.1186/s12957-018-1436-0. [PubMed] [PMC free article].

Elliyanti A, Susilo VY, Setiyowati S, Ramli M, Masjhur J, Achmad T. Uptake and Cytotoxicity Characterization of Radioiodine in MCF-7 and SKBR3 Breast Cancer Cell Lines. Atom Indonesia. 2016; 42(3):145-9. doi: 10.17146/aij.2016.586.

Okarvi SM, AlJammaz I. Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas. Molecules. 2019; 24(17):E3142. doi: 10.3390/molecules24173142. PubMed] [PMC free article].

Beyer S, Jimenez RE, Shapiro CL, Cho J, Jhiang SM. Do cell surface trafficking impairments account for variable cell surface sodium iodide symporter levels in breast cancer?. Breast Cancer Res Treat. 2009; 115(1):205-12. doi: 10.1007/s10549-008-0059-5. [PubMed] [PMC free article].

Wapnir IL, van de Rijn M, Nowels K, Amenta PS, Walton K, Montgomery K, et al. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab. 2003; 88(4):1880-8. doi: 10.1210/jc.2002-021544. [PubMed].

Knostman KA, McCubrey JA, Morrison CD, Zhang Z, Capen CC, Jhiang SM. PI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancer. BMC Cancer. 2007; 7:137. doi: 10.1186/1471-2407-7-137. [PubMed] [PMC free article].

Metso S, Auvinen A, Huhtala H, Salmi J, Oksala H, Jaatinen P. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer. 2007; 109(10):1972-9. doi: 10.1002/cncr.22635. [PubMed].

Riley AS, McKenzie GAG, Green V, Schettino G, England RJA, Greenman J. The effect of radioiodine treatment on the diseased thyroid gland. Int J Radiat Biol. 2019; 95(12):1718-1727. doi: 10.1080/09553002.2019.1665206. [PubMed].